Alto Neurosciences Discontinues ALTO-101 After Phase 2 Trial Fails to Meet Primary Endpoint

April 3, 2026

FDA Gives Reproxalap the Red Light For Dry Eye Disease

April 4, 2025

Tvardi Therapeutics Reports Phase 2 Failure for IPF Drug Candidate TTI-101

October 17, 2025

Must Read

Top 10 Digital Commercial Excellence Strategies

August 30, 2026

AI-Powered Protocol Design

August 30, 2026

J&J Gets First-Ever FDA Label Expansion For Imaavy

August 30, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Novo Launches Late-Stage Trial of Lower-Dose Wegovy Pill for Weight Management

Oregon Study Finds Triple-Drug Regimen Kept Infant Macaques HIV-Free for One Year

Summit and Akeso Report Updated HARMONi Survival Data for Ivonescimab in Western NSCLC Patients

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Another late-stage victory for Tezspire is achieved by AstraZeneca and Amgen, this time in esophagitis

Despite a mid-stage failure, Bausch + Lomb moves a medication for dry eye condition to Phase 3

Biokin’s Iza-Bren Meets Primary Endpoint in Phase 3 Panku-Lung01 Lung Cancer Trial

Definium Bags Major Phase 3 Victory With LSD Formula

Roche Licenses Hanmi’s HM17321 Obesity Candidate in Deal Worth Up to $2.3 Billion

Leo Pharma Pens Mega Deal to Buy Tanabe’s Skin Disease Drug

PTC Therapeutics Acquires ST-920 Fabry Disease Gene Therapy Program From Sangamo

Suki Launches AI Dictation Tool Integrated With Epic and Meditech EHRs

Claryx Appears From Stealth to Deal with the $45B Hospital-Acquired Infections Issue

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Top 10 Digital Commercial Excellence Strategies

AI-Powered Protocol Design

How Digital Twins Are Transforming Drug Development

Why Every Pharma Company Needs a Unified Data Platform

Insights

Addressing Unmet Need in Treatment-Resistant Cancers Through Purposeful R&D

Editor Picks

Alto Neurosciences Discontinues ALTO-101 After Phase 2 Trial Fails to Meet Primary Endpoint

FDA Gives Reproxalap the Red Light For Dry Eye Disease

Tvardi Therapeutics Reports Phase 2 Failure for IPF Drug Candidate TTI-101

Must Read

Top 10 Digital Commercial Excellence Strategies

AI-Powered Protocol Design

J&J Gets First-Ever FDA Label Expansion For Imaavy

Hot Topics

About Us

Follow Us